Human iPSC-derived MSCs from aged individuals acquire a rejuvenation signature
The use of primary mesenchymal stem cells (MSC) is fraught with ageing-related shortfalls such as limited expansion and early senescence. Human induced pluripotent stem cells (iPSC) -derived MSCs (iMSCs) have been shown to be a useful clinically relevant source of MSCs that circumvent these ageing-associated drawbacks. The importance of this concept is manifested by the successful Phase 1 clinical trial for the treatment of GvHD by Cynata Therapeutics and the National Health Service- Regno Unito; a Phase 2 trial is planned for 2019. Nota, this trial is independent of the work carried out by Spitzhorn et al.-described below.
Interessato a sapere se i programmi clinici attuali, sviluppi della ricerca, o gli approcci terapeutici emergenti potrebbero essere rilevanti per la tua situazione?
Solo informazioni didattiche e di ricerca. Le decisioni mediche individuali dovrebbero essere prese consultandosi con operatori sanitari qualificati.
